Evidence map›Paper›PMID 39807336›Full record

ArticleActa pharmaceutica Sinica. B2024

Avenanthramide A potentiates Bim-mediated antineoplastic properties of 5-fluorouracil

Rong Fu, Zhangfeng Dou, Ning Li, Xueyuan Fan, Sajid Amin, Jinqi Zhang, Yuqing Wang, Zongwei Li, Zhuoyu Li, Peng Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Molecules (Basel, Switzerland) · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rong FuSchool of Basic Medical Sciences, Shanxi Medical University, Taiyuan 030001, China.
Zhangfeng DouDepartment of Gastroenterology, First Hospital of Shanxi Medical University, Taiyuan 030001, China.
Ning LiDepartment of Gastroenterology, First Hospital of Shanxi Medical University, Taiyuan 030001, China.
Xueyuan FanSchool of Life Science, Shanxi University, Taiyuan 030006, China.
Sajid AminDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy.
Jinqi ZhangInstitute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan 030006, China.
Yuqing WangInstitute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan 030006, China.
Zongwei LiSchool of Life Science, Anhui Medical University, Hefei 230032, China.
Zhuoyu LiInstitute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan 030006, China.
Peng YangInstitute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan 030006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoresistance to 5-fluorouracil (5-FU) is a significant challenge in treating colorectal cancer (CRC). Novel combined regimens to thwart chemoresistance are therefore urgently needed. Herein, we demonstrated that the combination of Avenanthramide A (AVN A) and 5-FU has significant therapeutic advantages against CRC. Mechanistically, AVN A directly binds to the S198 site of the histone lysine demethylase KDM4C to promote its degradation, which subsequently fosters H3K9me3 occupancy on the

Indexed as

5-FluorouracilAvenanthramide AColorectal cancerKDM4CMIR17HG

Identifiers

PMID39807336
PMCPMC11725033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.